about
2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesNonthoracotomy implantable defibrillator lead extraction: results and comparison with extraction of pacemaker leads.Clinical study of the laser sheath for lead extraction: the total experience in the United States.Intravascular pacemaker and defibrillator lead extraction: a state-of-the-art review.Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II): a randomized trial.The DAVID (Dual Chamber and VVI Implantable Defibrillator) II trial.Device features for managing patients with heart failure.Lead extraction in the contemporary setting: the LExICon study: an observational retrospective study of consecutive laser lead extractions.Initial experience with the Evolution mechanical dilator sheath for lead extraction: safety and efficacy.Extraction of implantable cardiac electronic devices.The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011.Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.Cardiac venous left ventricular lead removal and reimplantation following device infection: a large single-center experience.Biventricular pacing for heart failure patients on inotropic support: a review of 38 consecutive cases.Current status and future expectations for multisite pacing in heart failure.Pacing in heart failure: the benefit of resynchronization.Malfunctions in implantable cardiac devices: putting the risk in perspective.Implantable cardioverter-defibrillator FDA safety advisories: Impact on patient mortality and morbidity.Interventional electrophysiology and cardiac resynchronization therapy: delivering electrical therapies for heart failure.Follow-up of patients with new cardiovascular implantable electronic devices: are experts' recommendations implemented in routine clinical practice?Safety of magnetic resonance imaging of patients with a new Medtronic EnRhythm MRI SureScan pacing system: clinical study design.Design of the Pacemaker REmote Follow-up Evaluation and Review (PREFER) trial to assess the clinical value of the remote pacemaker interrogation in the management of pacemaker patients.Pacemaker and ICD leads: strategies for long-term management.HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations.Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: this document was endorsed by the American Heart Association (AHA).Follow-up of patients with new cardiovascular implantable electronic devices: is adherence to the experts' recommendations associated with improved outcomes?Insights from internet-based remote intrathoracic impedance monitoring as part of a heart failure disease management program.CRT or CRT-D devices? The case for 'high energy' devices.Infections associated with cardiac implantable electronic devices are misunderstood.MRI in patients with cardiac implantable electronic devices.Remote monitoring of cardiovascular devices: a time and activity analysis.2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management.Role of CMR imaging in risk stratification for sudden cardiac death.Magnetic resonance imaging conditional pacemakers: rationale, development and future directions.The impact of atrial fibrillation with rapid ventricular rates and device programming on shocks in 106,513 ICD and CRT-D patients.Pivotal trials of cardiac resynchronization therapy: evolution to therapy in mild heart failure.A Heart Rhythm Society Electrophysiology Workforce study: current survey analysis of physician workforce trends.Inhibition of Staphylococcus aureus biofilms by a novel antibacterial envelope for use with implantable cardiac devices.
P50
Q22306358-55C9E67A-D6AF-4DD7-A7F1-B835C982203AQ26864648-E0CE2D6C-EC78-4EB2-B25D-68CE9963B4C0Q29620107-437093B0-4371-4E1D-9159-74D327E336E5Q30821143-03BBA6D1-D643-4185-B78D-92BB545CF626Q31068495-01CFF8C6-103F-4246-9676-DFC7A1B94E4AQ31162732-69F89123-7186-43A4-8245-8333F345C73BQ33148932-B247F4C5-E0E6-4F0B-A7F3-640BE48437C1Q33157163-7C576480-70CF-4AC7-A4D2-894BCC01AB2FQ33159863-69BF3B8D-E1B8-4597-912B-C478EE3EEC90Q33530971-0D05A235-E9F4-45EA-B747-D0BD0DBF9838Q33546768-B24FD1F2-204C-4E29-B6AA-2CF4780B6490Q33958268-389BCF03-3ED3-4179-97EE-4BE476F7053BQ34035537-B019E388-8F0A-44CF-90DC-3D3E551B4A37Q34166289-7204FE79-6E3B-459D-B1E4-718C3B645918Q34365532-ADF1F8E4-AEF0-4D76-BC61-6CCD58B409B3Q34478416-8B0A366E-0924-4786-B073-484C5E2C5890Q34605406-E646F67D-55F5-4853-A50F-8CD3015A0B38Q35585684-6127BA5B-59D1-4133-ABF4-E59E3090732DQ36271995-98C7985C-DD50-495B-93D9-9A3E99F3F2ADQ36282839-CFCD182A-6DDF-4D91-8C15-B0F6FFACF07DQ36799004-00C3AEC9-B91E-4B81-9996-F561D3A59F59Q36806574-D273331B-6C7D-497C-9DEF-DB50C1FC77E4Q37069051-56401F69-B867-4195-832C-40CAF57FE730Q37127814-EB5B85DF-2870-4E42-8AC6-1A3890803CAAQ37130207-6669DB4C-DB2A-4711-A339-AAA7F6F7144FQ37190622-BE9E0B11-5C32-4295-9C2B-FF00C2B85DD6Q37533340-FD698EE9-93FC-4032-AE80-80F6651326DCQ37627394-64B8AFCA-6A5D-4807-AE75-AEDA6A3F9BC6Q37776004-223B6C7A-E169-4809-B445-B1E2C598E013Q37911367-7E3DB473-B8BC-42DC-AF88-5B985356B3EDQ37917580-2FF617B0-4B9B-49A2-9C14-65F955DCA4C2Q37992202-D25F667C-4672-49AA-A4FE-3BCCF4495C89Q38032125-7E383807-F8BA-4EED-A7C7-48E68FC16AB3Q38038846-68E23159-961E-4FA0-876D-8C5DF588D837Q38087672-D11C2CE4-4B77-4DBA-B684-63E9C7D2D032Q39535607-974FAF27-DB6F-44C8-87CB-936F0BEAE342Q39718533-9B35B098-FAD0-46A4-BB66-CE3BF26567E4Q39775680-7139D30B-E9F1-4D51-827A-AEE4EC5CD282Q39853550-3E223E60-8831-44FA-A109-F4D3513A3ED9Q39876260-7D2BDE1E-3DD9-4B95-B4A7-1A398A0C2339
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Bruce Wilkoff
@ast
Bruce Wilkoff
@en
Bruce Wilkoff
@es
Bruce Wilkoff
@nl
Bruce Wilkoff
@sl
type
label
Bruce Wilkoff
@ast
Bruce Wilkoff
@en
Bruce Wilkoff
@es
Bruce Wilkoff
@nl
Bruce Wilkoff
@sl
prefLabel
Bruce Wilkoff
@ast
Bruce Wilkoff
@en
Bruce Wilkoff
@es
Bruce Wilkoff
@nl
Bruce Wilkoff
@sl
P106
P21
P31
P496
0000-0001-8905-9233